MX2023011502A - Proteina de fusion inmunogenica. - Google Patents

Proteina de fusion inmunogenica.

Info

Publication number
MX2023011502A
MX2023011502A MX2023011502A MX2023011502A MX2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A MX 2023011502 A MX2023011502 A MX 2023011502A
Authority
MX
Mexico
Prior art keywords
acid sequence
amino acid
amino acids
fusion protein
immunogenic fusion
Prior art date
Application number
MX2023011502A
Other languages
English (en)
Spanish (es)
Inventor
Fischer Per Bo Pedersen
Original Assignee
Minervax Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minervax Aps filed Critical Minervax Aps
Publication of MX2023011502A publication Critical patent/MX2023011502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023011502A 2021-03-29 2022-03-29 Proteina de fusion inmunogenica. MX2023011502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21165674.9A EP4066854A1 (en) 2021-03-29 2021-03-29 Immunogenic fusion protein
PCT/EP2022/058309 WO2022207657A1 (en) 2021-03-29 2022-03-29 Immunogenic fusion protein

Publications (1)

Publication Number Publication Date
MX2023011502A true MX2023011502A (es) 2023-10-19

Family

ID=75277909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011502A MX2023011502A (es) 2021-03-29 2022-03-29 Proteina de fusion inmunogenica.

Country Status (12)

Country Link
US (1) US20240173394A1 (cg-RX-API-DMAC7.html)
EP (3) EP4066854A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512722A (cg-RX-API-DMAC7.html)
KR (1) KR20230163500A (cg-RX-API-DMAC7.html)
CN (1) CN117120081A (cg-RX-API-DMAC7.html)
AU (1) AU2022248869A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019757A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212987A1 (cg-RX-API-DMAC7.html)
IL (1) IL307256A (cg-RX-API-DMAC7.html)
MX (1) MX2023011502A (cg-RX-API-DMAC7.html)
WO (1) WO2022207657A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309225B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553166A1 (en) 2023-11-07 2025-05-14 MinervaX ApS Method for preparing a sample for analysis
EP4748392A1 (en) 2024-11-20 2026-05-27 MinervaX ApS Vaccine formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
EP0656014B1 (en) 1993-03-19 2003-05-14 LINDAHL, Gunnar Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
PT2144924T (pt) * 2007-04-16 2016-08-17 Minervax Aps Vacina de proteína de fusão
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
WO2017114655A1 (en) * 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus

Also Published As

Publication number Publication date
ZA202309225B (en) 2025-03-26
AU2022248869A9 (en) 2023-11-09
BR112023019757A2 (pt) 2023-10-31
US20240173394A1 (en) 2024-05-30
EP4786002A2 (en) 2026-08-05
CA3212987A1 (en) 2022-10-06
IL307256A (en) 2023-11-01
KR20230163500A (ko) 2023-11-30
EP4313134A1 (en) 2024-02-07
AU2022248869A1 (en) 2023-10-26
JP2024512722A (ja) 2024-03-19
WO2022207657A1 (en) 2022-10-06
EP4066854A1 (en) 2022-10-05
CN117120081A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
WO2022043551A3 (en) Multivalent nucleic acid based coronavirus vaccines
Babapoor et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection
SI2280721T1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy
JP2015214545A5 (cg-RX-API-DMAC7.html)
JP2019504030A5 (cg-RX-API-DMAC7.html)
ES2586418T3 (es) Vacuna de proteína de fusión
RU2014134365A (ru) Вакцины против clostridium difficile, включающие рекомбинантные токсины
ZA202309225B (en) Immunogenic fusion protein
RU2018116601A (ru) Иммунногенный слитый белок
DK3072523T3 (en) COMPOSITION FOR PREVENTION AND TREATMENT OF INFECTIONS WITH MYCOPLASMA
WO2023042099A3 (en) Vaccines for coronavirus prevention and treatment
AR079712A1 (es) Composiciones inmunogenicas; kit y vacuna
RU2018122755A (ru) Слитые белки fmdv-e2 и их применение
MX2025010274A (es) Composiciones para su uso en el tratamiento de clamidia
RU2019115303A (ru) Вакцинные конструкты и их применения против инфекций стафилококка
AR100824A1 (es) Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae
MX2025013140A (es) Composiciones para el uso en el tratamiento del acne
JP2024512722A5 (cg-RX-API-DMAC7.html)
WO2005083072A1 (ja) 大腸菌における豚丹毒菌表層防御抗原変異体の製造方法
AR127169A1 (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
WO2014185817A3 (ru) Вакцина для профилактики и лечения ротавирусной инфекции, содержащая гибридный белок в качестве активного агента (варианты)
US9889192B2 (en) Immunization with rabies virus vector expressing foreign protein antigen
WO2014045084A1 (es) Proteínas de fusión con representación de diferentes alergenos: propuesta de vacuna para alergia a los ácaros
MX2020001055A (es) Vacuna contra la malaria.
CN1909925B (zh) 一种免疫佐剂